Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs

Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs.

Treatment of pain in rheumatoid arthritis must take into account the gastrointestinal and cardiovascular risk of individual patients. Adequate results are not yet available, and until they are, treatment recommendations must take into account, not only the more favourable gastrointestinal risk profile of selective COX-2 inhibitors, but also the potential atherothrombotic risk of any NSAID or se...

Non-steroidal anti-inflammatory drugs.

Safety of non-steroidal anti-inflammatory drugs.

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in medical practice for treating pain, inflammation and degenerative joint diseases (for instance, arthritis). The use of traditional NSAIDs (tNSAIDs), however, is associated with an increased risk of minor and serious gastrointestinal (GI) events. It is estimated that in the European Union thousands of gastrointestinal complication...

Isobolographic antinociception of non-steroidal anti-inflammatory drugs in rodent formalin orofacial pain

Diverse studies suggest that non-steroidal anti-inflammatory drugs (NSAIDs) induce antinociception through inhibition of cyclooxygenases. In this study was evaluated the effect of NSAIDs to induce antinociception either alone or in combination in the formalin orofacial test of rodent. Male mice were injected intraperitoneally with dexibuprofen, dexktoprofen, diclofenac meloxicam, metamizol, and...

[Non-steroidal anti-inflammatory drugs (NSAIDs)].

©2017 Blue Cross and Blue Shield of Louisiana An independent licensee of the Blue Cross and Blue Shield Association No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana. Page 1 of 4 Applies to all products admini...